Children's oncology Group's 2013 blueprint for research: Rare tumors

Carlos Rodriguez-Galindo, Mark Krailo, Lindsay Frazier, Murali Chintagumpala, James Amatruda, Howard Katzenstein, Marcio Malogolowkin, Logan Spector, Farzana Pashankar, Rebecka Meyers, Gail Tomlinson

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

In the US, approximately 2,000 children are diagnosed with rare cancers each year, with 5-year survival ranging from <20% for children with advanced carcinomas to >95% for children with intraocular retinoblastoma or localized germ cell tumors. During the last years, 12 clinical studies have been successfully completed in children with retinoblastoma, liver tumors, germ cell tumors, and infrequent malignancies, including therapeutic, epidemiologic, and biologic studies. Current efforts are centered in the development of large international collaborations to consolidate evidence-based definitions and risk stratifications that will support international Phase 3 clinical trials in germ cell tumors, hepatoblastoma, and other rare cancers.

Original languageEnglish (US)
Pages (from-to)1016-1021
Number of pages6
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2013

    Fingerprint

Keywords

  • Germ cell tumors
  • Hepatoblastoma
  • Rare cancers
  • Retinoblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Rodriguez-Galindo, C., Krailo, M., Frazier, L., Chintagumpala, M., Amatruda, J., Katzenstein, H., Malogolowkin, M., Spector, L., Pashankar, F., Meyers, R., & Tomlinson, G. (2013). Children's oncology Group's 2013 blueprint for research: Rare tumors. Pediatric Blood and Cancer, 60(6), 1016-1021. https://doi.org/10.1002/pbc.24428